Nymox Announces First Patient Enrollment for Phase 2 Prostate Cancer Clinical Trial

Nymox Pharmaceutical Corporation

is pleased to announce the first patient enrolment for Study NX03-0040, the Company's Phase 2 Study of NX-1207 for low risk localized prostate cancer. NX-1207 is also in Phase 3 development in the U.S. and Europe for benign prostatic hyperplasia (BPH). Preclinical studies of NX-1207 have shown activity against prostate cancer cells at higher dosage levels of NX-1207 than the dosage used in the current Phase 3 BPH clinical trials. The new study will test both low and high doses of NX-1207 for their effect on low grade localized prostate cancer. Efficacy in the study will be assessed 6 weeks after NX-1207 treatment.